ANTI-SCARRING GENE THERAPY
Investors
The Gene Therapy Boom
Gene therapy is one of the hottest growth areas in biotech with about $10 -20 Billion invested annually over the last several years.​ Cellastra is targeting unmet needs in Burn Care, Surgery & viral infect such as RSV, Influenza and COVID. The Long COVID syndrome, reported after COVID 19 infection, is characterized by pulmonary fibrosis and has been referred to as a $3.5 Trillion challenge (David Cutler, Harvard Economist).
​
Cellastra is developing a novel gene therapy utilizing a proprietary AAV6 vector and the genetic code for a naturally occurring peptide during normal wound healing.​
Severe Pulmonary Fibrosis, Burn Injuries, and Global Health Concerns
Severe pulmonary fibrosis can be caused by influenza, RSV or COVID 19 infections. After burn injuries, "a global epidemic", 70- 90 % may suffer from life-long severe scarring, chronic pain and compromised function. While any dermal injury could be targeted, novel gene therapy is limited initially to serious indications like patients requiring surgery to remove severe scarring from a previous surgery.​
Cellastra solutions to the problem
The FIBREXA Gene Therapy inhaled once and programs the lung epithelium to produce ensereptide, a natural peptide, which may help mitigate root causes of tissue damage and scarring during the acute phase of the infection.
​
The SCARLEXA Gene Therapy applied in the wound area in burn injuries or after surgery, switches on the production of natural anti-scarring peptides, which have already been found to be safe and effective in clinical studies to date. Rather than trying to apply topical treatment for weeks or months, one treatment with SCARLEXA turns on the production of the peptide at the site of the injury for many weeks or months.
​
Cellastra offers SOLID SCIENCE - NEAR TERM GROWTH OPPORTUNITY.
See contacts information below.
